These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11249693)

  • 1. RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson.
    Barnard DL
    Curr Opin Investig Drugs; 2000 Dec; 1(4):421-4. PubMed ID: 11249693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza.
    Young D; Fowler C; Bush K
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1905-13. PubMed ID: 11779391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.
    Birnkrant D; Cox E
    N Engl J Med; 2009 Dec; 361(23):2204-7. PubMed ID: 19884645
    [No Abstract]   [Full Text] [Related]  

  • 4. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.
    Sidwell RW; Smee DF
    Expert Opin Investig Drugs; 2002 Jun; 11(6):859-69. PubMed ID: 12036429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
    Mancuso CE; Gabay MP; Steinke LM; Vanosdol SJ
    Ann Pharmacother; 2010; 44(7-8):1240-9. PubMed ID: 20516360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
    Reina J
    Rev Esp Quimioter; 2006 Dec; 19(4):317-22. PubMed ID: 17235399
    [No Abstract]   [Full Text] [Related]  

  • 7. Peramivir for the treatment of influenza.
    Shetty AK; Peek LA
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
    Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs: Lines of defence.
    Palmer R
    Nature; 2011 Dec; 480(7376):S9-10. PubMed ID: 22158299
    [No Abstract]   [Full Text] [Related]  

  • 10. Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers.
    Iyer GR; Liao S; Massarella J
    AAPS PharmSci; 2002; 4(4):E22. PubMed ID: 12645994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing.
    Drusano GL; Preston SL; Smee D; Bush K; Bailey K; Sidwell RW
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2115-8. PubMed ID: 11408232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
    Bantia S; Upshaw R; Babu YS
    Antiviral Res; 2011 Sep; 91(3):288-91. PubMed ID: 21722670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
    Hurt AC; Ho HT; Barr I
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):795-805. PubMed ID: 17140356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation.
    Komeda T; Ishii S; Itoh Y; Ariyasu Y; Sanekata M; Yoshikawa T; Shimada J
    J Infect Chemother; 2015 Mar; 21(3):194-201. PubMed ID: 25523716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza.
    Med Lett Drugs Ther; 2015 Feb; 57(1461):17-9. PubMed ID: 25629811
    [No Abstract]   [Full Text] [Related]  

  • 16. Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents.
    Mineno T; Miller MJ
    J Org Chem; 2003 Aug; 68(17):6591-6. PubMed ID: 12919021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201.
    Sidwell RW; Smee DF; Huffman JH; Barnard DL; Morrey JD; Bailey KW; Feng WC; Babu YS; Bush K
    Antiviral Res; 2001 Sep; 51(3):179-87. PubMed ID: 11448729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zanamivir: from drug design to the clinic.
    Elliott M
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research progress of neuraminidase inhibitors for anti-influenza].
    Liu AL; Wang HD; Yang F; Du GH
    Yao Xue Xue Bao; 2009 Sep; 44(9):935-42. PubMed ID: 20055166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase inhibitor resistance in influenza viruses.
    Reece PA
    J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.